Rapport Therapeutics, Inc. (RAPP) Live Share Price, Invest From India

Rapport Therapeutics, Inc. Stock Performance

as on September 4, 2026 at 2:15 pm IST

Day's Low
Day's High
$47.08
Day's Price Range
$49.13
$47.65
1.20%
Downside
3.11%
Upside
52 Week's Low
52 Week's High
$14.11
52-Week Price Range
$52.93
$47.65
70.39%
Downside
11.08%
Upside

Rapport Therapeutics, Inc. share price movements today

Previous Close: $48.69
Open: $48.75
Volume: 314.8K
Market Cap: $2.3B
Day's Low - High: $47.08 - $49.13
52 Week Low - High: $14.11 - $52.93

Rapport Therapeutics, Inc. Historical Returns

1 Month Return: + 18.5 %
3 Month Return: + 39.14 %
1 Year Return: + 196.64 %
3 Year Return: 0 %
5 Year Return: 0 %

Rapport Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Rapport Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.3B

EPS (TTM)

-4.0933

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-39.96%

Rapport Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Rapport Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Rapport Therapeutics, Inc.	StrongBuy	$2.3B	NA	NA	0.00%	NA
Revolution Medicines	BUY	$44.6B	614.61%	NA	0.00%	NA
Vertex Pharmaceuticals	BUY	$137.9B	174.9%	31.92	86.04%	NA
Moderna	BUY	$61.6B	-61.21%	-7.98	-12.57%	NA
Regeneron	BUY	$82.3B	21.91%	19.9	84.86%	0.44%

Stock Returns calculator for Rapport Therapeutics, Inc. Stock including INR - Dollar returns

The Rapport Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Rapport Therapeutics, Inc. investment value today

Current value as on today

₹3,12,240

Returns

₹2,12,240

(+212.24%)

Returns from Rapport Therapeutics, Inc. Stock

₹1,91,081 (+191.08%)

Dollar Impact

₹21,159 (+21.16%)

Analyst Recommendation on Rapport Therapeutics, Inc. Stock

Based on 10 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 10 analysts, 100% of analysts recommend a 'BUY' rating for Rapport Therapeutics, Inc.. Average target price of $60.25

Indian Investors' Interest in Rapport Therapeutics, Inc. Stock

Search interest for Rapport Therapeutics, Inc. Stock has decreased by -34% in the last 30 days, reflecting a downward trend in search activity.

Time period: August 5, 2026 to September 4, 2026

Change:-34% versus previous 30 day period

Rapport Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	-	-	-	0	-	-	-	-	20	-
Gross Profit	0	0	0	0	0	0	0	0	20	-
Operating Income	-17	-20	-21	-23	-27	-29	-29	-38	-24	-60
EBITDA	-16	-20	-21	-23	-26	-29	-29	-38	-23	-56
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-22	-18	-17	-19	-24	-26	-26	-33	-19	-56
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-22	-18	-17	-19	-24	-26	-26	-33	-19	-56
Net Profit Margin	0.00%	0.00%	0.00%	-2775.00%	0.00%	0.00%	0.00%	0.00%	-99.29%	0.00%

Rapport Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-
Gross Profit	0	0	-1
Operating Income	-36	-83	-125
EBITDA	-36	-82	-124
Interest Expense	-	-	-
Depreciation	0	0	1
Income Before Tax	-34	-78	-111
Income Tax Expense	0	-	-
Net Income	-34	-78	-111
Net Profit Margin	0.00%	0.00%	0.00%

Rapport Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-18	-17	-19	-24	-26	-26	-33	-19	-56
Operating Cash Flow	-16	-16	-14	-20	-25	-17	-24	-13	-41
Investing Cash Flow	-107	-53	31	21	22	-56	-174	37	25
Financing Cash Flow	159	-1	0	0	0	270	0	0	1
Change in Cash	35	-70	17	0	-2	196	-198	25	-14

Rapport Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Net Income	-34	-78	-111
Operating Cash Flow	-27	-64	-87
Investing Cash Flow	-78	-170	-187
Financing Cash Flow	145	221	270
Change in Cash	39	-13	-4

Mutual Funds that own Rapport Therapeutics, Inc. Stock

Check out the Mutual Funds with significant holdings in Rapport Therapeutics, Inc..

Funds	Holdings	Shares Held
Goldman Sachs Trust	0.09068%	43507
Bridge Builder Trust	0.069612%	33399
Principal Funds, Inc	0.182255%	87443
VANGUARD WORLD FUND	0.171225%	82151
SCHWAB CAPITAL TRUST	0.169468%	81308

See all

Global Institutional Holdings in Rapport Therapeutics, Inc.

Funds	Holdings
Fidelity	0.06%
Xtrackers	0.06%
Nuveen	0.06%
Michael Rockefeller	0.2%
Avantis	0.12%

See all

Insights on Rapport Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, RAPP stock has moved up by 62.4%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 513.1% return, outperforming this stock by 302.7%

About Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Organisation	Rapport Therapeutics, Inc.
Headquarters	99 High Street, Boston, MA, United States, 02110
Industry	Biotechnology
CEO	Mr. Abraham N. Ceesay M.B.A.
E-voting on shares	Click here to vote

Key Management of Rapport Therapeutics, Inc.

Name	Title
Mr. Abraham N. Ceesay M.B.A.	CEO, President, Treasurer & Director
Dr. Jeffrey Sevigny M.D.	Chief Medical Officer
Ms. Cheryl Gault	Chief Operating Officer
Mr. Swamy Yeleswaram Ph.D.	Chief Development Officer
Dr. Steven M. Paul M.D.	Founder & Independent Chairman
Mr. Troy A. Ignelzi	Chief Financial Officer
Dr. David Bredt M.D., Ph.D.	Founder & Chief Scientific Officer
Ms. Karina Chmielewski	Chief Information Officer & Head of Operations
Ms. Julie DiCarlo	Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson	Chief People Officer

FAQs

What is Rapport Therapeutics, Inc. share price today?

Rapport Therapeutics, Inc. share price today is $47.65 as on September 4, 2026 at 8:45 am IST at the close of the market. Rapport Therapeutics, Inc. share today touched a day high of $49.13 and a low of $47.08.

What is the 52 week high and 52 week low for Rapport Therapeutics, Inc. share?

Rapport Therapeutics, Inc. share touched a 52 week high of $52.93 on August 27, 2026 and a 52 week low of $14.11 on September 4, 2025. Rapport Therapeutics, Inc. stock price today i.e. September 4, 2026 at 8:45 am IST is closed at $47.65,which is 9.98% down from its 52 week high and 237.70% up from its 52 week low.

What is Rapport Therapeutics, Inc.'s market capitalisation today?

Rapport Therapeutics, Inc. market capitalisation is $0.00T as on September 4, 2026 at 8:45 am IST.

How to invest in Rapport Therapeutics, Inc. Stock (RAPP) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Rapport Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Rapport Therapeutics, Inc. Shares that will get you 0.0315 shares as per Rapport Therapeutics, Inc. share price of $47.65 per share as on September 4, 2026 at 8:45 am IST.

What is the minimum amount required to buy Rapport Therapeutics, Inc. Stock (RAPP) from India?

Indian investors can start investing in Rapport Therapeutics, Inc. (RAPP) shares with as little as ₹94.475 or $1 (as of September 4, 2026 at 10:46 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹944.75 in Rapport Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on September 4, 2026 at 10:46 am IST). Based on Rapport Therapeutics, Inc. share’s latest price of $47.65 as on September 4, 2026 at 8:45 am IST, you will get 0.2099 shares of Rapport Therapeutics, Inc.. Learn more about fractional shares .